{
    "name": "Factor VIIa, recombinant",
    "comment": "Rx",
    "other_names": [
        "NovoSeven RT",
        "Sevenfact",
        "factor VIIa recombinant-jncw"
    ],
    "classes": [
        "Coagulation Factors",
        "Hemostatics"
    ],
    "source": "https://reference.medscape.com/drug/novoseven-rt-sevenfact-factor-viia-recombinant-342155",
    "pregnancy": {
        "common": [
            "There are no adequate and well-controlled studies in pregnant women to determine whether there is a drug-associated risk"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Data are not available regarding presence in human milk, effect on breastfed infants, and effects on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Serious arterial and venous thrombotic and thromboembolic events following administration reported",
                "Discuss risks and explain signs and symptoms of thromboembolic events with patients",
                "Monitor for signs or symptoms of activation of the coagulation system and for thrombosis"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [],
            "specific": []
        },
        "cautions": {
            "common": [
                "NovoSeven RT: Hypersensitivity to mouse, hamster, bovine protein, or any components of the product",
                "Neutralizing antibodies may develop; if inadequate hemostasis occurs after dosing, suspect development of antibodies and perform testing as clinically indicated"
            ],
            "specific": [
                {
                    "type": "Thromboembolism",
                    "description": [
                        "Serious arterial and venous thrombotic reactions can occur with FVIIa",
                        "Risk may be further increased with history of congenital or acquired hemophilia receiving concomitant treatment with aPCC/PCC (activated or non-activated prothrombin complex) or other hemostatic agents; history of atherosclerotic disease, coronary artery disease, cerebrovascular disease, crush injury, septicemia, or thromboembolic event",
                        "Monitor for signs and symptoms",
                        "Consider dose reduction when laboratory confirmation is available of intravascular coagulation or presence of clinical thrombosis"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Simultaneous use with activated prothrombin complex concentrates or coagulation factor XIII increases risk of serious thrombotic events "
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Infusion",
            "percent": null
        },
        {
            "name": "site discomfort",
            "percent": null
        },
        {
            "name": "Infusion",
            "percent": null
        },
        {
            "name": "site hematoma",
            "percent": null
        },
        {
            "name": "Infusion",
            "percent": null
        },
        {
            "name": "related reaction",
            "percent": null
        },
        {
            "name": "Fever",
            "percent": null
        }
    ]
}